China National Registry of Neuro-Inflammatory Diseases

Large prospective cohort studies allow long-term observation and analysis of the clinical status and disease activity of IDD patient population, and are the best way to understand IDD's natural course, clinical outcome, and drug efficacy in specific populations. Globally, several large prospective follow-up cohort studies have been conducted, providing important information on the disease characteristics of IDD patients. However, there is no large nationwide registry study of CNS IDD in China, and therefore there is a relative lack of data on the natural course of disease and drug efficacy in the Chinese IDD patient population, as well as a lack of standardized follow-up management of Chinese IDD patients. This study will establish a large prospective cohort study database of Chinese IDD, which will record detailed electronic information on IDD patients. We aim to establish a national (multicenter) disease registry for central nervous system idiopathic inflammatory demyelinating diseases in China, and to establish a unified standardized follow-up management process and treatment guidelines for patients with IDD in China; To provide real world data on the disease status of Chinese IDD patients; To understand the disease progression characteristics of IDD in China; To search for biological and imaging markers that predict the relapse, progression, and prognosis of IDD; to investigate the efficacy, safety, compliance and switch of different disease-modifying drugs (DMDs) in the long-term treatment of Chinese patients with IDD.

The study is a prospective observational (non-interventional) national multicenter cohort study to collect clinical data from IDD patients who have signed informed consent, to routinely and regularly follow up IDD patients on multiple clinical indicators, and to assess clinical outcomes. All information is to be completed prospectively from the time point the patient visited the hospital (except for Basic patient information and information about previous disease that are required at enrollment follow-up).Once the project started, the study sites are not allowed to discontinue the study on their own until the end of study is announced. In addition, to ensure the continuity of the data, each site needs to appoint designated clinical data collectors to collect data from qualified inpatient clinical cases consecutively, so as to ensure the consecutive registration of each inpatient case who meets the inclusion and exclusion criteria.

As the purpose of this study is to establish a national multicenter disease registry to provide disease-related information on patients with IDD in China, and the primary and secondary endpoints of the study being descriptive endpoints, therefore no formal calculation of sample size is needed. 10000 IDD patients are planned to be recruited.

• The brain structural change over time between the baseline MRI and the follow-up MRIs [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• The spinal cord change over time between the baseline MRI and the follow-up MRIs. [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Change of the central vein sign at 7T MRI. [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Change of rim of iron at 7T MRI. [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Change in High-contrast Letter Acuity (HCLA) over time at baseline and during follow-up in patients with IDD [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Change in Low-contrast Letter Acuity (LCLA) over time at baseline and during follow-up in patients with IDD [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Percentage Change in Spectral-domain Optical Coherence Tomography (SD-OCT) Average Retinal Nerve Fiber Layer (RNFL) Thickness at baseline and every year. [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Percentage change in SD-OCT Average Retinal Ganglion Cell Layer/Inner Plexiform Retinal Layer (RGCL/IPL) every year. [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Changes in cognitive function of patients with IDD at baseline and over time during follow-up [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Number of Participants with Adverse Events as a Measure of Safety and Tolerability [Срок оценки: From baseline to 5 years]
• NF-L level in serum. [Срок оценки: baseline, year1, year2, year3, year4, year5.]
• Determination of serum autoimmune antibodies [Срок оценки: baseline, year1, year2, year3, year4, year5.]